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Abstract
Background: Patients with Chagas disease have migrated to cities, where obesity, hypertension and other cardiac risk
factors are common.
Methodology/Principal Findings: The study included adult patients evaluated by the cardiology service in a public hospital
in Santa Cruz, Bolivia. Data included risk factors for T. cruzi infection, medical history, physical examination,
electrocardiogram, echocardiogram, and contact 9 months after initial data collection to ascertain mortality. Serology
and PCR for Trypanosoma cruzi were performed. Of 394 participants, 251 (64%) had confirmed T. cruzi infection by serology.
Among seropositive participants, 109 (43%) had positive results by conventional PCR; of these, 89 (82%) also had positive
results by real time PCR. There was a high prevalence of hypertension (64%) and overweight (body mass index [BMI] .25;
67%), with no difference by T. cruzi infection status. Nearly 60% of symptomatic congestive heart failure was attributed to
Chagas cardiomyopathy; mortality was also higher for seropositive than seronegative patients (p=0.05). In multivariable
models, longer residence in an endemic province, residence in a rural area and poor housing conditions were associated
with T. cruzi infection. Male sex, increasing age and poor housing were independent predictors of Chagas cardiomyopathy
severity. Males and participants with BMI #25 had significantly higher likelihood of positive PCR results compared to
females or overweight participants.
Conclusions: Chagas cardiomyopathy remains an important cause of congestive heart failure in this hospital population,
and should be evaluated in the context of the epidemiological transition that has increased risk of obesity, hypertension
and chronic cardiovascular disease.
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Introduction
Chagas disease, caused by the parasite Trypanosoma cruzi,
affects an estimated 8 million people in the Americas [1].
Transmission occurs via inoculation of T. cruzi-infected feces of
t h et r i a t o m i n ev e c t o rt h r o u g ht h eb i t ew o u n do rm u c o s a l
surfaces. Infection may also be acquired congenitally, through
blood transfusion, organ transplant or through consumption of
contaminated food or drink. The acute phase is associated with
high level parasitemia, and mild, non-specific symptoms in the
majority of individuals [2]. After 8–12 weeks, infected
i n d i v i d u a l sp a s si n t ot h ec h r o n i cp h a s e ,i nw h i c hp a r a s i t e sa r e
no longer detectable by peripheral blood microscopy and
d i a g n o s i sr e l i e so nd e m o n s t r a t i o no fa n t i - T. cruzi antibodies.
Infection is life-long in the absence of successful treatment. Over
a period of decades, 20–30% of infected individuals develop
specific patterns of end-organ damage. The most common form,
chronic Chagas cardiomyopathy, is characterized by conduction
system abnormalities, brady- and tachyarrhythmias, dilated
cardiomyopathy, apical aneurysm, and thrombus formation in
the aneurysm or enlarged left ventricle [3]. Patients with Chagas
heart disease have a high rate of mortality from ventricular
arrhythmias, pulmonary or cerebral emboli, and intractable
congestive heart failure [3].
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rural areas of Latin America where poor housing conditions
promoted vector infestation. Since 1991, Chagas disease control
programs have made striking progress in decreasing vector- and
blood-borne T. cruzi transmission, leading to dramatic declines in
infection prevalence among children [4,5]. However, millions of
T.cruzi-infected adults remain, and massive population movements
over the past 3 decades have brought many of these individuals to
cities across Latin America. Urban populations are in transition
from an epidemiology of predominantly infectious diseases to
patterns similar to industrialized countries where obesity, hyper-
tension, diabetes and atherosclerosis are the leading causes of
illness and death [6,7]. Adults infected with T. cruzi as children
form a transitional generation, experiencing the simultaneous
impact of past infectious exposures and current cardiovascular risk
factors.
Bolivia has the highest prevalence of T. cruzi infection in the
world, estimated at 6% of the national population, and reaching
30–40% in surveys of pregnant women, blood donors or endemic
community members [1,8,9,10]. The major objective of this study
was to assess T. cruzi cardiac morbidity and its coincidence with
common cardiovascular risk factors and disease among patients
attending a large urban public hospital. In addition, we explored
risk factors for T. cruzi infection and disease severity, and clinical
and epidemiological associations with positive results by T. cruzi
PCR.
Methods
Ethics statement
The protocol was approved by the institutional review boards of
the study hospital, Asociacio ´n Bene ´fica PRISMA, and the Centers
for Disease Control and Prevention.
Study site and patient population
The study was conducted in the Hospital Universitario Japone ´s
in Santa Cruz, Bolivia from August 25 to November 13, 2008.
The hospital is one of two public hospitals and serves
approximately 60% of the city’s uninsured population. Although
the city of Santa Cruz does not have vector-borne T. cruzi
transmission, infection prevalence is high because many residents
migrated from rural areas with intense transmission. All patients
attending the cardiology clinic, admitted to the cardiology
inpatient service or seen by the cardiology service in inpatient
consultations were eligible, with the exception of those younger
than 18 years, pregnant, unable to provide informed consent or
unable to undergo cardiac evaluation.
After written informed consent, a structured questionnaire was
administered by a study nurse. Data included demographics and
factors potentially associated with T. cruzi infection risk (e.g., type
of housing, location of and infestation in residences throughout
life, family history of sudden death and Chagas disease, history of
transfusion). Each patient underwent a focused history and
physical examination, electrocardiogram (EKG) and echocardio-
gram. The study physician and two cardiologists who performed
the echocardiograms and interpreted the EKGs were blinded to
patient infection status. Data on existing structural heart disease or
risk factors for structural heart disease were collected from medical
records, EKGs and echocardiograms. A 12-ml blood specimen
was obtained from each participant, centrifuged and separated
into serum and clot. In August 2009 (9 months after the
completion of the cross-sectional study), telephone contact was
attempted for all participants or their family members to ascertain
whether the patients were alive. The date of death was sought for
those no longer alive at that time.
Laboratory methods
Serum specimens were screened for antibodies to T. cruzi using
two commercial enzyme-linked immunosorbent assays (ELISA),
one based on whole epimastigote lysate (Chagatek, bioMe ´rieux,
Buenos Aires, Argentina) and the other on recombinant antigens
(Chagatest, Wiener laboratory, Rosario, Argentina). Results were
interpreted following the manufacturers’ instructions. For discor-
dant results, an immunofluorescent antibody test (IFA) was
performed using a titer of 1:32 as the positive cut-off. A patient
was considered to have confirmed T. cruzi infection if he or she had
positive results by at least two serologic tests [11].
Polymerase chain reaction (PCR) was performed using 500 ml
specimens of clot, based on an earlier analysis showing higher
sensitivity in this specimen compared to buffy coat or whole blood
[12].DNA was extracted following a standard phenol-chloroform
extraction protocol [13].PCR amplifications were performed using
the 121/122 primer set (5-AAATAA- TGTACGGGKGAGATG-
CATGA-3 and 5-GTTCGATTGGGGTTGGTGTAATATA-3)
targeting the kinetoplast minicircle, using published methods and
conditions [12,14].A positive result was based on the appearance
of the characteristic 330-bp product [12].
Quantitative real time PCR followed published methods
[15].The primer set Cruzi 1 (59–ASTCGGCTGATCGT-
TTTCGA–39) and Cruzi 2 (59–AATTCCTCCAAGCAGCG-
GATA–39) was used to amplify a 166 base-pair DNA fragment.
The probe Cruzi 3 (59–CACACACTGGACACCAA–39) was
labeled with 59FAM (6 – carboxyfluorescein) and 39MGB (minor
groove binder). TaqMan Human RNase-P detection reagent
(Applied Biosystems) was included as an internal control. A result
was considered valid only when the internal control was efficiently
amplified. A non-template negative control was included in each
run. A positive result was defined by the threshold cycle (Ct), the
first cycle where fluorescence was detected above baseline. The
C(t) was determined by the respective standard curve for the
specimen batch, and was always between 37 and 38 cycles. A clot
specimen was inoculated with 1610
6 T. cruzi Y strain trypomas-
tigotes, extracted and diluted successively to determine the
minimum quantity detectable; the limit was found to be 1
parasite/ml [8,15].
Author Summary
Latin America is undergoing a transition from disease
patterns characteristic of developing countries with high
rates of infectious disease and premature deaths to a
pattern more like industrialized countries, in which chronic
conditions such as obesity, hypertension and diabetes are
more common. Many rural residents with Chagas disease
have now migrated to cities, taken on new habits and may
suffer from both types of disease. We studied heart disease
among 394 adults seen by cardiologists in a public hospital
in the city of Santa Cruz, Bolivia; 64% were infected with T.
cruzi, the parasite that causes Chagas disease. Both T. cruzi
infected and uninfected patients had a high rate of
hypertension (64%) and overweight (67%), with no
difference by infection status. Nearly 60% of symptomatic
congestive heart failure was due to Chagas disease;
mortality was also higher for infected than uninfected
patients. Males and older patients had more severe Chagas
heart disease. Chagas heart disease remains an important
cause of congestive heart failure in this hospital popula-
tion, but often occurs in patients who also have obesity,
hypertension and/or other cardiac risk factors.
Chagas Cardiomyopathy and Chronic Disease
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The American College of Cardiology and American Heart
Association (ACC/AHA) heart failure classification system was
applied for all patients with available echocardiograms [16]. For
T. cruzi-infected patients, we also assigned a severity classification
based on a slight modification of published methods:[17]
1. Stage A: T. cruzi infection with normal EKG and echocardio-
gram
2. Stage B: T. cruzi infection with EKG abnormalities and/or
minor echocardiogram abnormalities (segmental wall motion
abnormalities, left atrial dilatation, apical aneurysm, diastolic
dysfunction) with preserved systolic function (ejection fraction
(EF) $55%) and no left ventricular dilatation
3. Stage C: T. cruzi infection with mild to moderate systolic
dysfunction (EF 40–54%) and/or left ventricular dilatation
4. Stage D: T. cruzi infection with severe systolic dysfunction (left
ventricular end diastolic diameter $57 mm, EF #40% and
NYHA classification III or IV).
Stages were not assigned for infected subjects whose clinical and
echocardiogram findings indicated an etiology other than Chagas
cardiomyopathy. All other T. cruzi-infected patients with echocar-
diogram data were assigned a Chagas cardiomyopathy stage,
regardless of the presence or absence of comorbidities.
Hypertension, diabetes, coronary disease were defined based on
patient history and/or physician documentation in the medical
record chart. Body mass index (BMI) was calculated (weight in
kilograms divided by the square of the height in meters).
Statistical analysis
Cross-sectional analyses were performed in SAS version 9.2
(SAS Institute) for three outcome measures: (1) T. cruzi infection
among all subjects; and (2) positive T. cruzi PCR results and (3)
Chagas cardiomyopathy severity stage among T. cruzi-infected
subjects only. Categorical variables were compared by the exact
Pearson’s chi-square test; continuous variables were analyzed
using the Wilcoxon rank-sum test. Variables significant at a=0.05
were considered for multivariable logistic regression models, and
appropriate 2-way interactions were tested.
Results
Study population and clinical status
Of 549 patients seen by the cardiology service during the study
period, 394 (72%) enrolled in the study. Three excluded patients were
pregnant, 8 were younger than 18 years, 44 declined participation,
and 100 left the hospital prior to contact with the research staff. One
patient failed to meet the serological criteria for confirmed infection
(positive results by Wiener ELISA, negative by Chagatek ELISA and
IFA) but had positive results by T. cruzi PCR; this patient was
excluded from the epidemiological analyses. Of the 393 patients
included in the analysis, 65% were female. The mean age was 52.0
years (range 20–86) for females and 51.4 years (18–87) for males. The
prevalence of confirmed T. cruzi infection was 63.9% (251/393).
Overall, 64% of participants had a history of hypertension and 67%
were overweight or obese (defined as body mass index [BMI] .25).
Other markers or risk factors for structural heart disease were less
common. Of the 342 patients with ACC/AHA staging data, 155
(45%) had stage C or D, indicating symptomatic congestive heart
failure; of these, 91 (58.7%) had Chagas cardiomyopathy, whereas 23
(14.8%) had T. cruzi infection but another probable etiology for their
cardiac insufficiency.
Chagas cardiomyopathy severity stage was assigned for 191 T.
cruzi-infected patients: 27 (14.1%) stage A (equivalent to
indeterminate), 97 (50.8%) stage B, 51 (26.7%) stage C and 16
(8.4%) stage D. Chagas severity stage was not determined for the
38 T. cruzi-infected patients whose heart disease was judged to be
from another etiology. This group included 2 patients with isolated
left ventricular hypertrophy (LVH), 2 with left atrial dilatation
associated with severe mitral stenosis or mitral valve prolapse, 26
with diastolic dysfunction and/or LVH due to hypertensive
disease, 4 with segmental hypokinesis and systolic dysfunction in
setting of an acute coronary syndrome, and 1 each with a
pericardial tumor and congenital heart disease. Twenty-two
infected patients were lacking echocardiogram data and could
not be assigned a Chagas severity stage for that reason.
Of the 393 patients in the analysis, survival status 9 months after
completion of the cross-sectional study was determined for 325 (83%);
25 (7.7%) patients died during that time, but dates of death were only
availablefor 19, precluding a formalsurvivalanalysis. PatientswithT.
cruzi infection were more likely to have died than those without
infection (21/210 (10%) versus 4/115 (3%); p=0.05). However, the
strongest predictor of death was ACC/AHA heart failure stage: 19
(15%) of 125 patients with stage C or D died, compared to 0 (0%) of
59 with stage A and 1 (1%) of 102 with stage B (p,0.001). Of the 19
patients with ACC/AHA stage C or D, 15 (79%) had Chagas disease;
t h eo n ed e c e a s e dp a t i e n tw i t hA C C / A H As t a g eBa l s oh a dC h a g a s
disease. Five of the deceased patients, all with T. cruzi infection, had
not had echocardiograms and therefore were missing ACC/AHA
stage data.
Associations with T. cruzi infection
Males and females were equally likely to have T. cruzi infection
(Table 1). Infected patients were older than uninfected patients
(mean 53.7 vs. 48.3 years, p=0.001). T. cruzi infection prevalence
increased with age to a peak at approximately 58 for males and 69
for females, and then declined, demonstrating a significant
quadratic relationship. Age was therefore included as a quadratic
function in models with T. cruzi infection as the outcome.
The prevalence of hypertension, coronary artery disease, diabetes
and BMI.25 did notdiffer among T.cruzi-infected versusuninfected
patients(Table1).Therewerenosignificantdifferencesinfindingsfor
overweight (BMI 25–29.9) compared to obese patients (BMI .30).
Wetherefore used a combined category that included overweight and
obesity. In both unadjusted and adjusted analyses, T. cruzi-infected
patients had significantlyhigher prevalence of arrhythmias and severe
congestive heart failure as measured by ACC/AHA classification,
andwere more likelyto have been recruited fromtheinpatient service
compared to uninfected patients. In the model adjusted for age and
sex,infected patients were less likelyto report coronary artery disease;
this difference was borderline significant. There were no differences
by infection status in the frequency of valvular heart disease,
congenital heart disease, stroke, or transitory ischemic attacks, or of
reported symptoms such as dizziness or lightheadedness, syncope,
palpitations, typical or atypical chest pain, exertional dyspnea,
dysphagia, or constipation (data not shown, but available upon
request). Infected and uninfected patients were equally likely to have
an implanted pacemaker (14/251 versus 5/142; p=0.47).Inmodels
adjusted for age and sex, T. cruzi-infected patients were significantly
more likely than uninfected patients to have a right bundle branch
block (RBBB), left ventricular dilatation, ‘pure’ left atrial dilatation
(defined as left atrial end diastolic diameter .40 mm not explained
by diastolic dysfunction or LVH), low ejection fraction, diffuse wall
motion abnormalities, apical aneurysm or intracavitary thrombi, and
less likely to have LVH (Table 2).
Chagas Cardiomyopathy and Chronic Disease
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poor housing conditions and increasing duration of residence in an
endemic province were associated with increased risk of T. cruzi
infection, with a significant interaction between the latter two
variables (Table 3). For each additional decade living in an
endemic province, people who lived in poor housing experienced a
3.2-fold increase risk of T. cruzi infection compared a 1.7-fold
increase for those who lived in moderate or good housing.
Severity of Chagas cardiomyopathy
In univariate analyses, increasing age (odds ratio [OR] per 10-
year increase in age 1.40; 95% confidence interval [CI] 1.09–
1.81), male sex (OR 5.87; 95% CI 3.04–11.31), having lived in
poor housing (OR 2.46; 95% CI 1.29–4.71) and decades living in
an endemic province (OR 1.24; 95% CI 0.99–1.54) were
associated with elevated risk of severe disease, defined as Chagas
cardiomyopathy stage C or D. Having BMI .25 was associated
with a trend to decreased risk of severe disease (OR 0.56; 95% CI
0.29–1.10). In a multivariable model, male sex, increasing age and
poor housing remained strong predictors of severe disease
(Table 4). In the adjusted models, no significant association was
detected for other variables (including BMI .25, hypertension,
coronary artery disease, or diabetes, positive results by PCR, prior
treatment for T. cruzi infection, and cumulative time living in an
infested house or rural area).
Associations with positive results by T. cruzi PCR
Of 251 patients with confirmed positive results by serology, 109
(43%) had positive results by conventional PCR, and of these, 89
(81.7%) also had positive results by real time PCR. Among
specimens with positive results by real time PCR, the median
number of parasite copies/mL was 79.4 (range 1.1 – 313,330).
One patient (excluded from the epidemiological analyses) had
positive results by 1 of 3 serological tests, but positive results by
conventional and real time PCR. If this patient is considered
uninfected based on the serological results, both conventional and
real time PCR had calculated specificities of 99.3% (142/143).
Specimens with positive results by PCR had higher mean
Chagatek and Wiener ELISA absorbance values (defined as
optical density minus ELISA plate cut-off value) than those with
negative PCR results (median Chagatek absorbance 1.34 vs. 1.23,
p=0.006; Wiener 2.28 vs. 2.21, p,0.001). However, the
distribution of absorbance values for specimens positive and
negative by PCR had a high degree of overlap. There was no
difference in ELISA absorbance values by Chagas severity stage
(P=0.73).
Epidemiological associations with positive results by conven-
tional PCR and real time PCR were similar. Among seropositive
participants, males were significantly more likely than females to
have positive results by conventional PCR (OR 2.16; 95% CI
1.28–3.65) or by real time PCR (OR 1.830; 95% CI 1.03–3.26). In
additional univariate analyses, positive conventional PCR results
were less frequent among patients with BMI .25 (OR 0.40; 95%
CI 0.22–0.71), a history of hypertension (OR 0.54; 95% CI 0.31–
0.92) or signs of left atrial dilatation on echocardiogram (OR 0.50;
95% CI 0.29–0.85). There was no association between severity of
heart failure or Chagas cardiomyopathy and positive results by
conventional or real time PCR. In a multivariable logistic
regression model adjusted for age and disease severity, male sex
remained associated with higher odds and BMI .25 with lower
odds of positive results by conventional PCR (Table 5). Parasite
load as measured by real time PCR was higher among males than
Table 1. Characteristics of seropositive and seronegative study participants.
Characteristic
Seropositive
(N=251) n (%)
Seronegative
(N=142) n (%)
P value
(Unadjusted)
a
P value
(Adjusted)
b
Gender
Male 90 (35.9) 48 (33.8) 0.7417 0.4092
Female 161 (64.1) 94 (66.2) … …
Type of recruitment
Inpatient cardiology service/consultation 62 (24.7) 20 (14.1) 0.0140 0.0107
Outpatient clinic 189 (75.3) 122 (85.9) … …
Structural heart disease and/or risk factors
Hypertension
c 149 (64.0) 86 (64.2) 1.0000 0.1148
Coronary artery disease 37 (14.7) 25 (17.6) 0.4734 0.0731
Diabetes
d 42 (19.7) 20 (16.5) 0.5586 0.6277
Arrhythmia 49 (19.5) 13 (9.2) 0.0091 0.0286
Body mass index $25
e 154 (69.4) 83 (61.9) 0.1648 0.7889
ACC/AHA Heart Failure Classification
f
Stage A 49 (21.4) 16 (14.2) 0.0007 ,0.0001
Stage B 66 (28.8) 56 (49.6) … …
Stage C or D 114 (49.8) 41 (36.3) … …
aUnadjusted results based on exact Pearson chi-square tests.
bAdjusted results based on logistic regression, adjusted for gender and age as a quadratic function. Note that gender is adjusted for age as a quadratic function only.
See text for explanation of age adjustment.
cData missing for 18 seropositive and 8 seronegative patients.
dData missing for 38 seropositive and 21 seronegative patients.
eData missing for 29 seropositive and 8 seronegative patients.
fData missing for 22 seropositive and 29 seronegative patients.
doi:10.1371/journal.pntd.0000688.t001
Chagas Cardiomyopathy and Chronic Disease
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no difference by BMI category (P=0.94).
Discussion
A profound epidemiological and nutritional transition has been
underway in Latin America for the last several decades [7,18,19].
In some countries, such as Chile and Uruguay, a pattern of non-
communicable disease epidemiology similar to the United States
or Europe is now predominant [18]. In other countries, such as
Guatemala and Bolivia, the rural population still lives in pre-
transitional conditions with limited access to adequate housing,
diet, clean water and sanitation [20]. However, when the rural
poor migrate to cities, they often experience an abrupt transition
to more sedentary lives and calorie-dense diets, and may add
obesity, diabetes and hypertension to pre-transition conditions,
including Chagas disease [21].
Our data offer a graphic illustration of the challenge facing
health care systems in T. cruzi-endemic areas. We found that 59%
of congestive heart failure cases were attributable to Chagas
cardiomyopathy, and 79% of deaths in patients with advanced
congestive heart failure occurred in those with Chagas disease.
Table 2. EKG and echocardiogram findings among patients with and without Trypanosoma cruzi infection.
Seropositive
n( % )
Seronegative
n( % )
P value
(Unadjusted)
a
P value
(Adjusted)
b
EKG findings
c
Atrial fibrillation/flutter 25 (11) 6 (4) 0.0501 0.0938
Any ventricular arrhythmia
d 13 (5) 3 (2) 0.1864 0.3758
Left anterior fascicular block 28 (12) 11 (8) 0.2941 0.4448
Right bundle branch block 41 (17) 9 (7) 0.0041 0.0116
Bifascicular (right bundle and left anterior fascicular) block blocks)
e 19 (8) 3 (2) 0.0221 0.1107
Abnormality 1
st portion of QRS 55 (23) 17 (12) 0.0139 0.0568
Left ventricular hypertrophy 21 (9) 22 (16) 0.0433 0.0500
Echocardiogram findings
e
Left ventricular dilatation
f 50 (22) 13 (10) 0.0087 0.0114
‘‘Pure’’ left atrial dilatation
g 43 (19) 14 (11)
h 0.0696 0.0296
Ejection fraction ,55% 62 (27) 18 (14) 0.0053 0.0162
Diffuse wall motion abnormality 39 (17) 8 (6) 0.0050 0.0087
Apical aneurism 23 (10) 1 (1) 0.0006 0.0187
Intracavitary thrombus 22 (10) 2 (2) 0.0033 0.0279
Left ventricular hypertrophy 49(21)
h 38 (30) 0.0940 0.0045
Diastolic dysfunction 112 (49) 61 (48) 0.9121 0.1319
aUnadjusted results based on exact Pearson chi-square tests.
bAdjusted results based on logistic regression, adjusted for sex and age as a quadratic function. See text for explanation of age adjustment.
cEKG analyses include a total of 237 seropositive and 137 seronegative participants. 14 seropositive and 5 seronegative participants were excluded from the EKG
analyses because they had implanted pacemakers.
dDenominator for ‘any ventricular arrhythmia’ includes 14 seropositive and 5 seronegative participants with pacemakers excluded from the other EKG analyses.
eEchochardiogram analyses include 229 seropositive and 127 seronegative participants.
fDefined as end diastolic diameter .57 mm.
gDefined as left atrial end diastolic diameter .40 mm not explained by diastolic dysfunction or left ventricular hypertrophy.
hData missing for one participant.
doi:10.1371/journal.pntd.0000688.t002
Table 3. Multivariable logistic regression model of factors associated with risk of Trypanosoma cruzi infection.
Risk Factors
a Odds Ratio 95% Confidence Intervals
Gender (male vs. female) 1.25 0.73–2.15
Ever lived in rural area 2.07 1.12–3.83
Ever lived in poor housing (house with both adobe walls and dirt floor)
a 2.65 1.51–4.65
10-year increase in residence in an endemic province
b
Among those with good to intermediate housing 1.71 1.37–2.14
Among those with poor housing 3.20 2.14–4.78
Data missing for 7 patients.
aResults for each risk factor are adjusted for other variables listed and for age as a quadratic function; see text for explanation.
bSignificant interaction between years of residence in an endemic area and housing. Risk associated with housing conditions evaluated holding years in endemic area
fixed at the mean (45.2 years).
doi:10.1371/journal.pntd.0000688.t003
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failure cases and 8% of congestive heart failure deaths attributed to
Chagas disease in facility-based data from Brazil and Argentina
reviewed in a recent publication [22], and illustrate the very high
disease burden still caused by T. cruzi in Bolivia today.
Nevertheless, a majority of both T. cruzi-infected and uninfected
patients in Santa Cruz had additional cardiovascular risk factors
such as hypertension, obesity and diabetes. Although the
increasing burden of chronic non-infectious disease in developing
countries is well recognized [22], there are no published data
regarding potential interactions of these conditions with infectious
diseases such as T. cruzi. Our data represent a first snapshot of
their co-occurrence and highlight issues that merit further
investigation, including more comprehensive assessment of
cardiovascular risk factors and co-morbidities, population-based
disease burden assessments, and longitudinal follow-up to evaluate
prognosis and disease progression over time.
Our study suffers from the inherent limitations of facility-based
data: patterns may reflect differences in health care seeking
behavior rather than biological differences, and the magnitude of
the morbidity burden does not reflect what would be found in a
population-based study because patients with more severe disease
are more likely to seek care than those with milder disease.
Consistent with the published literature [23,24,25], we found male
sex to be associated with a substantially increased risk of severe
Chagas heart disease. As expected from the chronic progressive
nature of the cardiomyopathy, severity also increased steadily with
age. The fall-off in seroprevalence among older adults in endemic
communities has long been attributed to excess mortality among
infected individuals as their heart disease worsened after age 45
[26,27]. Survival is markedly shortened among Chagas cardio-
myopathy patients once they have heart failure or other indicators
of advanced cardiomyopathy [25,28,29]. We also observed similar
age- and sex-related patterns. However, because our data are
facility-based, we cannot rule out the possibility that they reflect
differences in health care access.
Morbidity and mortality from Chagas disease tend to occur at
an older age now than previously [30], and this may be reflected in
the older age of peak seroprevalence in our data compared to
earlier studies. In part, this represents a cohort effect: as vector
control has decreased exposure and infection incidence among
younger people, Chagas disease is becoming a disease of older
adults [30]. In addition, better clinical management and health
care access may have improved survival, especially for those living
in urban areas [31]. Many experts also believe that intense
exposure to infected vectors and repeated T. cruzi reinfection
contributed to accelerated progression of cardiomyopathy and
high rates of severe disease in the decades before the Southern
Cone Initiative began in 1991, and that vector control has led to
an amelioration of Chagas cardiomyopathy since then [32,33,34].
Although this hypothesis is difficult to test in human populations,
animal models provide supporting evidence that repeated infection
worsens the long-term prognosis of Chagas heart disease [35]. We
observed that patients who had lived in a house with earthen floor
and walls were more likely to have severe Chagas cardiomyopathy;
this finding may reflect poor housing conditions acting as a proxy
for more intense vector exposure and reinfection risk.
Our clinical findings are consistent with many published studies,
demonstrating associations with right bundle branch block, left
ventricular dilatation, low ejection fraction, apical aneurysms, and
intracavitary thrombi [3]. The risk factors for infection identified
in our data were not surprising, and as shown in many previous
studies, included markers for or consequences of poverty, such as
lower educational level, rural upbringing and having lived in
houses with adobe walls and earthen floors. The intensification of
risk seen when poor quality housing was combined with longer
residence in an endemic province underscores the importance of
maintaining both vector control and housing improvement
programs in rural Bolivia, where infestation has not yet been
eliminated [36].
We found no consistent association between parasite burden as
indicated by positive PCR results and disease severity; this
negative finding may result from the limitations of the cross-
sectional design or the molecular methods, or may reflect the
pathophysiology of the disease. In the last 10 years, a consensus
has emerged that parasite persistence underlies the development
and progression of Chagas cardiomyopathy [34,37]. In a study of
left ventricular heart muscle tissue from necropsies of patients who
died with different stages of chronic Chagas cardiomyopathy, a
positive association among inflammation, fibrosis and parasite
DNA was found [38]. Other authors endorse the importance of
parasite persistence in tissue the pathogenesis of chronic Chagas’
cardiomyopathy [39,40] Nevertheless, demonstration of a quan-
titative link between parasite burden and cardiac pathology or
disease severity has been elusive [34]. This failure may be due in
part to the limitations of existing detection methods. PCR assays,
while more sensitive that culture or xenodiagnosis, are imperfect
[41]. Sampling biases may also exist: when multiple specimens are
examined, whether by xenodiagnosis, culture or PCR, many
individuals have detectable parasitemia on some occasions but not
others and parasite levels in peripheral blood may not correlate
well with parasite loads in target tissues such as the heart [41,42].
In a life-long infection such as Chagas disease, the question of
timing is also essential. In theory, the impact of parasite load on
pathology could occur early but with enduring effects. In an earlier
study of 56 infected individuals, positive PCR results at baseline
was predictive of increased progression risk over a several-year
period of longitudinal follow-up [23]. In contrast, other studies
Table 4. Multivariable logistic regression model of factors
associated with severity of Chagas cardiomyopathy, defined
as Chagas stage C or D (versus Chagas stage A or B).
Factor Odds Ratio
95% Confidence
Intervals
Male sex 7.06 3.44–14.47
10-year increase in age 1.54 1.15–2.07
Ever lived in a house with both
adobe walls and dirt floor
2.23 1.08–4.62
doi:10.1371/journal.pntd.0000688.t004
Table 5. Multivariable model of characteristics associated
with positive results on conventional Trypanosoma cruzi PCR
among seropositive patients.
Factor Odds Ratio
95% Confidence
Intervals
10-year increase in age 0.94 0.72–1.22
Male sex 2.51 1.17–5.36
Chagas stage C/D (vs. A/B) 0.67 0.31–1.47
Overweight or obese (BMI $25) 0.44 0.22–0.87
Data missing for 96 patients.
doi:10.1371/journal.pntd.0000688.t005
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of parasitemia and cardiomyopathy progression [24,41,42].
We found intriguing epidemiological associations with T. cruzi
PCR results. Males were significantly more likely to have positive
PCR results than females, and obesity was associated with a lower
prevalence of positive results. Animal models suggest that male
gonadal hormones decrease immune control of the parasite [43].
Orchiectomy of male mice enhances clearance of T. cruzi infection
and reduces the amastigote burden in heart tissue, whereas
parasitemia levels increase when castrated mice receive supple-
mental testosterone. In female mice, the parasitemia level rises
after oophorectomy, and can be suppressed by estrogen and/or
progesterone supplementation [44]. To our knowledge, the
association of obesity with lower likelihood of positive results by
T. cruzi PCR has not previously been reported in a clinical study.
However, mouse models of chronic T. cruzi infection reveal large
numbers of parasites in adipocytes. Indeed, more parasites are
seen per adipocyte than in the tissues such as heart where parasites
are classically thought to reside during chronic infection,
suggesting that adipose tissue may represent a long-term reservoir
and potentially a parasite sink [45]. Further investigation is needed
to confirm the validity of these epidemiological observations and
their physiological significance.
One of our study participants had discordant serology and
positive PCR results; we excluded her from the epidemiological
analyses, because her results did not meet the standard criteria for
confirmed chronic T. cruzi infection, which require at least 2
positive serological tests [11]. Nevertheless, we believe these results
reflected a true infection. Positive PCR results in specimens from
seronegative individuals have been reported in a number of
studies, reflecting the fact that none of the diagnostic options for
chronic T. cruzi infection has perfect sensitivity and specificity, and
any given set of test results should be interpreted with care
[41,46,47,48].
As control programs decrease T. cruzi incidence, attention is
shifting to the large number of adults infected before these
programs began. At the same time, T. cruzi-endemic countries are
experiencing population shifts, urbanization and the epidemiolog-
ical transition. Better understanding of the role of cardiac
comorbidities and metabolic factors in the course and evolution
of chronic Chagas cardiomyopathy will be essential to optimizing
management of these patients in the future.
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